The clinical evidence base for avacopan, a drug marketed as Tavneos and approved for two rare forms of vasculitis, has suffered a significant blow after the New England Journal of Medicine retracted the pivotal phase 3 trial that helped secure its regulatory approval. The retraction follows a formal investigation by the US Food and Drug Administration, which concluded that trial data had been
manipulated— the agency's own characterisation of the findings.
What Is Avacopan and Who Was It Approved For?
Tavneos received FDA approval in 2021 for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two rare and serious conditions in which inflammation damages small blood vessels throughout the body. Both conditions fall under the umbrella of ANCA-associated vasculitis, a group of disorders that can affect multiple organ systems and carry substantial mortality risk if left untreated. The drug's approval was considered a meaningful advance in a therapeutic area with limited options, making the integrity of the supporting trial data especially consequential.
The Retraction and What Preceded It
According to reporting by the BMJ, the New England Journal of Medicine moved to retract the study after the FDA's investigation surfaced concerns about the reliability of the underlying data. The journal indicated that two academic authors named on the pivotal phase 3 trial were involved in the retraction process, though the precise nature and scope of their involvement has not been fully detailed in public disclosures.
Data integrity investigations of this kind are relatively uncommon in high-profile regulatory science, and the FDA's willingness to characterise the problem in such direct terms signals the seriousness with which the agency viewed its findings. The retracted study had served as a cornerstone of the regulatory dossier submitted to support Tavneos approval, meaning its removal from the scientific record carries immediate practical implications.
European Regulators Move to Revoke Authorisation
The fallout has not been confined to the United States. The European Medicines Agency has separately recommended revoking the marketing authorisation for Tavneos across European Union member states, citing the same questions over data integrity that prompted the NEJM retraction. The EMA's recommendation represents a significant regulatory escalation and, if confirmed, would effectively remove the drug from European markets.
The near-simultaneous action by two of the world's most influential medicines regulators — the FDA maintaining active scrutiny while the EMA moves toward revocation — places the future of avacopan in serious doubt across multiple jurisdictions. Regulatory recommendations of this nature are rarely reversed without substantial new evidence.
Implications for Patients and the Broader Field
For patients currently receiving avacopan for GPA or MPA, the regulatory developments create a period of considerable uncertainty. Both conditions are serious, and treatment decisions in ANCA-associated vasculitis typically involve weighing the risks of active disease against those of immunosuppressive therapy. The retraction does not, on its own, establish that the drug is ineffective or unsafe — it establishes that the evidence previously used to demonstrate its benefits can no longer be considered reliable in its published form.
The episode also raises broader questions about the systems in place to detect data irregularities before — rather than after — regulatory approval. Phase 3 trials in rare diseases often involve relatively small patient populations, which can make statistical anomalies harder to detect during routine peer review. The FDA's post-approval investigation in this case suggests that more intensive data auditing may have been warranted earlier in the process.
Retraction in Context
High-profile retractions from journals of the New England Journal of Medicine's standing are uncommon but not without precedent. The journal has previously retracted studies linked to research misconduct, and each instance tends to prompt renewed debate about the robustness of pre-publication peer review and the degree to which regulatory agencies rely on published literature versus raw trial data submitted directly to agencies.
In this instance, the FDA's investigation appears to have been the catalyst rather than the journal's own review processes, a sequence that underscores the value of post-market regulatory surveillance. Whether the agency's findings will lead to further action — including potential enforcement measures against those responsible for the data — remains to be seen.
What Happens Next
The FDA has not publicly indicated whether Tavneos approval will be formally withdrawn in the United States, though the agency's ongoing scrutiny, as reported by the BMJ, suggests the matter remains active. The EMA's recommendation to revoke authorisation will proceed through its standard decision-making process before becoming binding on member states.
For the manufacturer, the dual regulatory pressure represents an existential challenge for the product. Avacopan had been positioned as a meaningful therapeutic option in a disease area where treatment advances have historically been slow, and its potential removal from multiple markets would leave clinicians managing GPA and MPA with a narrower set of approved options.
The retraction of the NEJM study, combined with the regulatory responses on both sides of the Atlantic, marks one of the more significant episodes of post-approval data scrutiny in recent years — and one whose full consequences for patients, regulators, and the broader clinical research enterprise are still unfolding.